{
    "id": 4744,
    "fullName": "TP53 R282W",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "TP53 R282W is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R282W results in decreased activation of Tp53 target genes, leads to resistance to apoptosis and failure of G1arrest in culture (PMID: 31395785), and additionally acquires neomorphic DNA binding sites (PMID: 31395785), inhibits Ampk signaling, leading to invasive growth and altered cell metabolism in culture and promotes tumor development in mouse models (PMID: 24857548).",
            "references": [
                {
                    "id": 2397,
                    "pubMedId": 22713868,
                    "title": "Mutant p53: one name, many proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22713868"
                },
                {
                    "id": 17772,
                    "pubMedId": 31395785,
                    "title": "A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31395785"
                },
                {
                    "id": 2456,
                    "pubMedId": 24857548,
                    "title": "Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24857548"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "R282W",
    "createDate": "04/13/2015",
    "updateDate": "02/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 95517,
        "transcript": "NM_000546",
        "gDna": "chr17:g.7673776G>A",
        "cDna": "c.844C>T",
        "protein": "p.R282W",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8700,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26375,
                "profileName": "KRAS G12V PIK3CA Q546K TP53 R282W"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8701,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26375,
                "profileName": "KRAS G12V PIK3CA Q546K TP53 R282W"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8600,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26375,
                "profileName": "KRAS G12V PIK3CA Q546K TP53 R282W"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4540,
            "profileName": "TP53 R282W",
            "profileTreatmentApproaches": [
                {
                    "id": 5344,
                    "name": "p53 Gene Therapy",
                    "profileName": "TP53 R282W"
                },
                {
                    "id": 5343,
                    "name": "p53 Activator",
                    "profileName": "TP53 R282W"
                }
            ]
        },
        {
            "id": 26375,
            "profileName": "KRAS G12V PIK3CA Q546K TP53 R282W",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 95516,
            "transcript": "NM_001126112",
            "gDna": "chr17:g.7673776G>A",
            "cDna": "c.844C>T",
            "protein": "p.R282W",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 95518,
            "transcript": "NM_001126113",
            "gDna": "chr17:g.7673776G>A",
            "cDna": "c.844C>T",
            "protein": "p.R282W",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 95517,
            "transcript": "NM_000546",
            "gDna": "chr17:g.7673776G>A",
            "cDna": "c.844C>T",
            "protein": "p.R282W",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 95519,
            "transcript": "NM_001126114",
            "gDna": "chr17:g.7673776G>A",
            "cDna": "c.844C>T",
            "protein": "p.R282W",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}